Ibandronic Acid Continues To Prevent Bone Loss Caused By Anastrozole In Women With Surgically Treated Breast Cancer
Ibandronic acid is an basic treatment option as post-menopausal women with antiquated breast cancer that suffer from low bone mineral density caused by adjuvant anastrozole group therapy, according to results from the ARIBON inspect presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. [1]
Although anastrozole is a highly effective and well tolerated treatment also in behalf of boob cancer, its wear and tear is associated with a decline in bone mineral density (BMD) and an increased jeopardy of bone fracture in some women.[2,3] The novel data show that monthly oral ibandronic acid (also known as ibandronate) treatment significantly increased bone mineral density1 and prevented bone loss caused by anastrozole in patients who were osteopenic (had compassionate thinning of the bones).
“The results are very reassuring as they show that the strengthening clout of monthly ibandronate at the needle and at the perceptive is maintained after two years,” said Dr Jim Lester, lead examine investigator, Cancer Research Centre, Weston Park Sickbay, Sheffield, UK. “Anastrozole is an important cure on account of breast cancer patients but we utterly want to reduce their risk of declining bone density and resultant fractures and osteoporosis. A bisphosphonate in memo pad form, taken for good occasionally-a-month, offers a promising mixing an eye to physicians prescribing anastrozole to breast cancer patients.”
The ARIBON study evaluated the impact of ibandronate, 150mg orally once a month, on BMD in post-menopausal early mamma cancer patients taking anastrozole. Differences in BMD change-over at the lumbar prickle after one year, between osteopenic patients enchanting anastrozole plus ibandronate and those in the placebo group was 5.5% (p